Track BIIB in your personal workspace
Monitor performance, SPY relative strength
and WOI View from your watchlist.
Alert me when BIIB price is:
52W Range Position
100%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-09-03 19:42 UTC
WOI Investment Thesis
Constructive
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Moderate / Positive / Healthy / Stretched
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
No reliable structural support level is currently available.
Not available
↗
Break Above
Primary setup trigger already cleared; this level remains the breakout reference.
219.72
🎯
Next Objective
Primary pattern objective while the setup remains active.
253.59
×
Thesis Break
Primary technical setup invalidates below this level.
Below 183.06
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
29
●
Financial Results
HIGH
BIIB reports financial results
The press release is being furnished pursuant to
8-K Filing•SEC EDGAR
JUL
1
●
Financial Results
HIGH
BIIB reports financial results
(Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis.
8-K Filing•SEC EDGAR
MAY
14
◆
M&A
HIGH
BIIB merger or acquisition update
CVR Agreement As previously disclosed, on March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly ow...
CVR Agreement As previously disclosed, on March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”).
8-K Filing•SEC EDGAR
What's Driving BIIB?
✓ Technical setup is active
Momentum is Neutral. Primary trigger is Above 219.72 with structure risk at Below 183.06.
◆ Business quality is mixed
Revenue growth is moderate. Profitability is positive. Cash generation is healthy. Balance-sheet quality is stretched.